article thumbnail

STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned

STAT

The International Federation of Pharmaceutical Manufacturers & Associations hailed the outcome. “Intellectual Property is a critical enabler for the development of medicines and vaccines.

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CDMO Live 2025 to spotlight the future of pharmaceutical outsourcing in Europe

Express Pharma

As the sector continues its rapid expansion, with a 7 per cent annual growth rate, the event will highlight the increasing reliance on contract development and manufacturing organisations (CDMOs) in bringing new therapies to market. ” CDMO Live has established itself as a key platform for the outsourcing ecosystem. .”

article thumbnail

Continuous manufacturing: Changing the paradigm in the pharmaceutical manufacturing sector

Express Pharma

The world massively relies on the developments that continue to take place in the pharmaceutical industry to experience an improved quality of life. Therefore, to successfully implement CM in every pharma manufacturing facility, the key focus should be key investments, advancing scientific and technical knowledge, and additional incentives.

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

IP is no barrier to COVID vaccine access, says industry

pharmaphorum

While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk.”.

article thumbnail

mRNA and beyond: Opportunities for US biologics

Outsourcing Pharma

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.